Abstract
Catheter ablation for rhythm control in atrial fibrillation has been recognized as an established treatment. Patients with atrial fibrillation suffer from an increased risk of thromboembolic events. Long-term stroke risk and mortality have been shown to be reduced after catheter ablation, still the procedure per se is associated with an additive peri-procedural thromboembolic risk. Maintenance of the thrombotic - bleeding equilibrium in such patients during interventional procedures is compelling. Lack of data from randomized studies along with the recent introduction of novel oral anticoagulants in clinical practice has resulted in a wide variance of antithrombotic treatment approaches. Procedural interruption of anticoagulants, switching of anticoagulation scheme (i.e. from novel oral anticoagulants to vitamin K antagonists), bridging with heparin, timing of re-initiation of therapy and/or utilization of novel oral anticoagulants have all been points of dispute. In the present review we present the available data regarding optimal peri-procedural anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation.
Keywords: Radiofrequency, cryoablation, VKA, NOAC, warfarin, dabigatran, rivaroxaban, apixaban.
Current Pharmaceutical Design
Title:Peri-procedural Anticoagulation in Catheter Ablation for Atrial Fibrillation: A Review
Volume: 23 Issue: 9
Author(s): Dimitrios A. Vrachatis*, Georgios Giannopoulos, Charalambos Kossyvakis, Vasiliki Panagopoulou, Manolis Vavuranakis, Theodore G. Papaioannou, Stamatina Pagoni, Vlasios N. Pyrgakis, Michael W. Cleman and Spyridon G. Deftereos
Affiliation:
- Department of Cardiology, “G. Gennimatas” General Hospital of Athens, 154 Mesogion ave., 115 27, Athens,Greece
Keywords: Radiofrequency, cryoablation, VKA, NOAC, warfarin, dabigatran, rivaroxaban, apixaban.
Abstract: Catheter ablation for rhythm control in atrial fibrillation has been recognized as an established treatment. Patients with atrial fibrillation suffer from an increased risk of thromboembolic events. Long-term stroke risk and mortality have been shown to be reduced after catheter ablation, still the procedure per se is associated with an additive peri-procedural thromboembolic risk. Maintenance of the thrombotic - bleeding equilibrium in such patients during interventional procedures is compelling. Lack of data from randomized studies along with the recent introduction of novel oral anticoagulants in clinical practice has resulted in a wide variance of antithrombotic treatment approaches. Procedural interruption of anticoagulants, switching of anticoagulation scheme (i.e. from novel oral anticoagulants to vitamin K antagonists), bridging with heparin, timing of re-initiation of therapy and/or utilization of novel oral anticoagulants have all been points of dispute. In the present review we present the available data regarding optimal peri-procedural anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation.
Export Options
About this article
Cite this article as:
Vrachatis A. Dimitrios*, Giannopoulos Georgios, Kossyvakis Charalambos, Panagopoulou Vasiliki, Vavuranakis Manolis, Papaioannou G. Theodore, Pagoni Stamatina, Pyrgakis N. Vlasios, Cleman W. Michael and Deftereos G. Spyridon, Peri-procedural Anticoagulation in Catheter Ablation for Atrial Fibrillation: A Review, Current Pharmaceutical Design 2017; 23 (9) . https://dx.doi.org/10.2174/1381612822666161205115101
DOI https://dx.doi.org/10.2174/1381612822666161205115101 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Commentary (Research Highlights Utilizing Neuro-Inflammation: Turning Degeneration to Regeneration)
CNS & Neurological Disorders - Drug Targets Adult Neurogenesis and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Biopsychosocial Predictors of Cognitive Impairment in the Elderly: A Case-control Study
Current Psychiatry Research and Reviews Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Current Pharmaceutical Design Stem Cell Therapy for the Treatment of Myocardial Infarction
Current Pharmaceutical Design Editorial [ NeuroAIDS: A Neuroscience Problem with Global Impact ]
Current HIV Research Relation of Obesity to Cognitive Function: Importance of Central Obesity and Synergistic Influence of Concomitant Hypertension. The Framingham Heart Study
Current Alzheimer Research Smoking and Eye Pathologies. A Systemic Review. Part II. Retina Diseases, Uveitis, Optic Neuropathies, Thyroid-Associated Orbitopathy
Current Pharmaceutical Design Targeting Hypoxia-Inducible Factor (HIF) as a Therapeutic Strategy for CNS Disorders
Current Drug Targets - CNS & Neurological Disorders The Promise of Plant-Derived Substances as Inhibitors of Arginase
Mini-Reviews in Medicinal Chemistry Inflammatory Cytokines in Acute Ischemic Stroke
Current Pharmaceutical Design Respiratory Gas Exchange During Exercise in Children with Congenital Heart Disease: Methodology and Clinical Concepts
Current Respiratory Medicine Reviews Comment on Patient Adherence to Novel Oral Anticoagulants (NOACs) for the Treatment of Atrial Fibrillation and Occurrence of Associated Bleeding Events: A Systematic Review and Meta-analysis
Current Vascular Pharmacology Aging Blunts Ischemic-Preconditioning-Induced Neuroprotection Following Transient Global Ischemia in Rats
Current Neurovascular Research Sphingolipid Signaling Pathways as Potential Therapeutic Targets in Gliomas
Mini-Reviews in Medicinal Chemistry Elevated Total Homocysteine Predicts In-Hospital Pneumonia and Poor Functional Outcomes in Acute Ischemic Stroke
Current Neurovascular Research The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Current Cancer Drug Targets Seeking Novel Targets for Improving In Vivo Macrophage-Specific Reverse Cholesterol Transport: Translating Basic Science into New Therapies for the Prevention and Treatment of Atherosclerosis
Current Vascular Pharmacology Neuroprotective Effects of Fisetin in Alzheimer’s and Parkinson’s Diseases: From Chemistry to Medicine
Current Topics in Medicinal Chemistry